The effect of nonsense mutations on mRNA levels is variable. The levels of some mRNAs are not affected and truncated proteins are produced, while the levels of others are severely decreased and null phenotypes are observed. The effect on mRNA levels is important for the understanding of phenotype-genotype association. Cystic fibrosis (CF) is a lethal autosomal recessive disease with variable clinical presentation. Recently, two CF patients with mild pulmonary disease carrying nonsense mutations (R553X, W1316X) were found to have severe deficiency of mRNA. In the Jewish Ashkenazi CF patient population, 60% of the chromosomes carry a nonsense mutation, W1282X. Patients homozygous for this mutation have severe disease presentation with variable pulmonary disease. The presence of CF transcripts in a group of patients homozygous and heterozygous for this mutation was studied by reverse transcriptase PCR of various regions of the gene. Subsequent hybridization to specific CF PCR probes and densitometry analysis indicated that the CF mRNA levels in patients homozygous for the W1282X mutation are not significantly decreased by the mutation. mRNA levels were compared for patients heterozygous for the W1282X mutation. The relative levels of mRNA with the W1282X, and the delta F508 or the normal alleles, were similar in each patient. These results indicate that the severe clinical phenotype of patients carrying the W1282X mutation is not due to […]
Introduction
Nonsense mutations, which code for premature termination of translation, can also affect the levels of mRNA. Some mRNA carrying nonsense mutations are present in normal levels, resulting in the production oftruncated proteins (1, 2) . However, the levels of many other mRNA with nonsense mutations are Adress correspondence to Dr. Bat sheva Kerem, Genetics Department, Life Sciences Institute, Hebrew University, Jerusalem 91904, Israel Receivedfor publication 21 April 1993 and in revisedform 24 November 1993. severely decreased, resulting in null phenotypes. Decreased mRNA levels due to nonsense mutations have been found in bacteria (3), yeast (4), mice (5) , and humans (6) (7) (8) (9) (10) (11) (12) (13) . Nonsense mutations in the f,-globin gene cause a 40 fold reduction in the half-life of ,B-globin mRNA in erythroid cells (14) . In the dihydrofolate reductase gene, nonsense mutations reduce the mRNA levels but the transcription and stability of the mature mRNA are normal (15) . In some cases, a polar effect is observed. For instance, immunoglobulin mRNAs with nonsense mutations in the 5' end oftheir coding regions are 100-fold less stable than mRNAs with nonsense mutations near the authentic termination codons (16) .
In cases in which the termination mutations cause diseases, an understanding of their effects on mRNA stability can aid in understanding the phenotype-genotype association. For example, the absence of f3-globin mRNA in the peripheral blood of patients homozygous for nonsense mutations causes #'-thalassemia, which is the most severe form of fl-thalassemia (17) .
Cystic fibrosis (CF)' is the most frequent autosomal recessive lethal disease in the Caucasian population (18) . The disease is characterized mainly by progressive lung disease, pancreatic dysfunction, impaired growth, and elevated sweat chloride (18) . The severity of the disease presentation and its rate of progression in the involved organs vary considerably. The gene responsible for the disease has been recently cloned and a major mutation, AF508, which accounts for 70% of the CF chromosomes, has been identified (19-21). A phenotype-genotype correlation in CF has been suggested, based on haplotype analysis and the different distribution ofthe AF508 mutation among pancreatic-sufficient and -insufficient patients (21, 22) . The AF508 mutation was shown to be associated with severe clinical presentation as reflected by early onset, pancreatic insufficiency, early age at diagnosis, poor nutritional status, high sweat chloride levels, and variable pulmonary function (23, 24) . Since the identification of the CF gene, > 300 mutations have been identified worldwide (25) . Several ofthese have been found to be associated with severe form of the disease, while others have been found to be associated with relatively mild presentation (26) .
Recently, two CF patients carrying nonsense mutations were reported to have severe deficiency of mRNA transcribed from the nonsense alleles (27) . One patient carried two different nonsense mutations, R553X and W1316X, and the second patient was heterozygous for the missense mutation, S549N, and the nonsense mutation, R553X. The R553X nonsense mutation is located in the first nucleotide binding fold of the CF transmembrane regulator (CFTR) protein, while the second nonsense mutation, WI 316X, is located in the second nucleotide binding fold close to the 3' end of the gene.
In the Ashkenazi Jewish CF population the frequency of the AF508 mutation is only 24%. Recently, a major mutation, W1282X, was found in 60% of the chromosomes carried by patients from this ethnic group (28) . This mutation creates a stop codon in exon 20 of the CF gene, which is located in the second nucleotide binding fold of the CFTR protein. Among patients of Jewish Ashkenazi origin -25% are homozygous for this nonsense mutation. We recently compared the clinical presentation of patients homozygous for the W1282X mutation and patients heterozygous for both the AF508 and the WI 282X mutations (28) . We found that patients in both groups have similar severe disease presentation as reflected by pancreatic insufficiency, high incidence of meconium ileus, early age at diagnosis, poor nutritional status, and variable pulmonary function. In this study we aimed to determine the effect of the nonsense mutation, W1282X, on mRNA levels in order to deepen our understanding ofthe genotype-phenotype association in CF.
Methods
Patients and controls. This study included five CF patients homozygous for the W1282X mutation, two CF patients homozygous for the AF508 mutation, two CF patients heterozygous for both the W1282X and the AF508 mutations, seven parents ofthe CF patients carrying the W1282X mutation, and a healthy Jewish Ashkenazi who does not carry any of the mutations known to account for 97% of the CF mutations in this ethnic group. This individual was considered a normal control. The patients' diagnoses had been confirmed before this study. The disease presentation ofthe patients has been described previously (28) .
RNA extraction and single-strand cDNA synthesis. Nasal epithelial cells were scraped from all the individuals studied. The cells were immediately placed in liquid nitrogen. For RNA extraction the cells were resuspended in 300 ,d RNAzolTm B buffer (BIOTECX Laboratories, Inc.). Total RNA was extracted using the acid-phenol-chloroform method according to the manufacturer's instructions.
RNA was solubilized in 10 g diethylpyrocarbonate (DEPC)-treated Polymerase chain reaction (PCR). The cDNA products were amplified by PCR (29, 30) . The oligonucleotide primers used for the amplification and the annealing temperatures for each PCR are listed in Table  I . Each reaction mixture contained the 20 ul of cDNA from the RT reaction, lx Taq buffer, 2.5 U of Taq polymerase (Boehringer Mannheim Biochemicals), 50 pmol of each oligonucleotide primer, and distilled water to bring the final volume to 100 Ml. For controls, we used 20 M1 ofthe reaction mixes from the RNA-less samples for cDNA synthesis (see previous section). cDNA samples were heated at 94°C for 3 min and then subjected to 35 cycles ofdenaturation (94°C for 30 s), primer annealing (as indicated in Table I) , and extension (65°C for 30 s), followed by a final extension period of 7 min. Nested RT-PCR products were generated for sequencing reactions, using the oligonucleotide primers FI R, Fl L, F2R, and F2L. The sequences ofthese oligonucleotides and the PCR conditions have been described previously (31).
Hybridization with allele-specific oligonucleotides and PCR products. 20 Ml of each RT-PCR sample were subjected to electrophoresis on a 1.4% agarose gel. Blots were prepared as previously described (28) . Filters were hybridized for 18 h with 5 X 106 cpm/ml of32P end-labeled oligonucleotides or 5 X 101 cpm/ml 32P random-primed specific genomic DNA-PCR products. The blots were washed twice at room temperature for 5 min, followed by two 15-min washes at 550C. Identification ofthe W1282X mutation by MnlI digestion. 25 M1 of RT-PCR products of exons 19-21 was digested with MnlI restriction endonuclease for 18 h at 370C and subjected to electrophoresis on 1.7% agarose gels. Blots were prepared and hybridized with exon 20 genomic DNA-PCR products as described above.
RT-PCR sequence determination. Nested RT-PCR products of exons 19-21 eluted from 5% polyacrylamide gels were extracted with phenol/chloroform and subjected to the dideoxy chain termination sequencing method (32) using the Sequenasem kit (U. S. Biochem.
Corp., Indianapolis, IN) with the F2R oligonucleotide as the sequencing primer.
Results
cDNA reverse transcribed from total nasal epithelial RNA was analyzed in five CF patients homozygous for the nonsense mutation WI 282X, two CF patients homozygous for the AF508 mutation, and a normal individual. The CF patients homozygous for the W1282X mutation were 1-32 yr old, all with pancreatic insufficiency. The pulmonary disease was mild in some patients and severe in the others. This variability was not correlated with age. Three regions of the CF gene were amplified by RT-PCR: upstream to the W1282X mutation, exons 9-11 (region I); flanking the mutation, exons 19-21 (region II); and downstream to the mutations, exon 21-23 (region III). The sequences of the oligonucleotide primers used in the RT-PCRs are listed in Table I . No PCR products could be seen on the ethidium bromide-stained agarose gels. Therefore, the RT-PCR products generated from regions I, II, or III were blotted and hybridized to the DNA-PCR products of exon 10, 20, or 21, respectively. The ,B-actin gene was amplified as a control for the overall amount of RNA extracted from the scraped nasal cells. These amplified products were hybridized to actin PCR products. DNA fragments of the predicted sizes were detected in all three regions of the CF and the actin genes in all patients (Fig. 1 ). The hybridization results revealed the existence of RT-PCR products from CF patients homozygous for the W1282X mutation. These results were verified by direct sequencing of the RT-PCR products generated from patients homozygous for the W1282X mutation. Nested RT-PCR was performed between exons 19 and 24 (as described in Methods) and the products were directly sequenced. The complete expected cDNA sequence, with the W1282X mutation, was found in all the RT-PCR products from patients homozygous for this mutation (Fig. 2) .
To study the relative levels of CFTR transcripts from WI 282X, AF508, and the normal alleles, cDNA from two patients heterozygous for both the AF508 and the W1282X mutations and from two healthy carriers of the W1282X mutation was amplified. In addition, cDNA was amplified from the same individuals, homozygous for either the W1282X mutation or the normal allele, as in the previous experiments. The amplified region was between exons 19 and 21. For controls, exon 20 genomic DNA was amplified from individuals homozygous for Similar Levels of W1282X and AF508 Cystic Fibrosis Allele mRNA 1503 the WI 282X mutation, from individuals heterozygous for the W1282X mutation and a normal allele, and from individuals carrying two normal alleles. Only PCR products from the DNA controls could be detected on the ethidium bromide-stained gel, therefore, the PCR products were blotted and hybridized to specific oligonucleotides detecting either the W1282X mutation (WM) or the normal sequence at this site (WN) (see Table I) .
Surprisingly, the WI 282X alleles could not be detected by the WM oligonucleotide in any of the RT-PCR products. Hybridization signals of the predicted sizes were detected only on the DNA-PCR controls (data not shown). Weak hybridization signals were detected in RT-PCR products ofindividuals carrying the normal exon 20 sequences using the WN oligonucleotide probe. An' oligonucleotide (WM') from the antisense strand was designed to detect the WI 282X mutation (Table I) , but no hybridization to the W1282X allele could be detected with this oligonucleotide either.
Hybridization to oligonucleotide probes designed to differentiate between CF the W1282X allele and the normal allele was not sensitive enough for our purposes. Therefore, we adopted our original technique, in which we detected RT-PCR products using genomic DNA-PCR products as probes. We took advantage ofthe fact that the W1282X mutation destroys a recognition site for the restriction enzyme MnlI. We digested the RT-PCR products from exons 19-21 with MnlI, before gel electrophoresis, blotting, and hybridization. To study the relative levels of CFTR transcripts from W1282X, AF508 and the normal alleles, relative intensity ofthe radioactive bands representing the W1282X and the normal or the AF508 alleles in each lane were analyzed. For this analysis we have enlarged the group of individuals heterozygous for the W1282X mutation. Thus, in these experiments were included two patients heterozygous for the AF508 and W1282X mutations, five healthy carriers of the W1282X mutation, three patients homozygous for the W1282X mutation, and one patient homozygous for the AF508 mutation. The RT-PCR products were from the same batches as had failed to give signals when hybridized with oligonucleotide probes (see previous section) and from additional three carriers of the W1282X mutation. The blots were hybridized to exon 20 genomic DNA-PCR products. The restriction map of the amplified region is shown in Fig. 3 . The MnlI-digested RT-PCR products from the heterozygous individuals revealed two bands: one of 204 bp and the other a 99 + 105-bp doublet; the 99-and the 105-bp bands are inseparable on the gel (Fig. 4 ). The first band is the expected size for the W 1282X allele and the second band is of the expected size for the AF508 or the normal alleles. The MnlI-digested RT-PCR products from individuals homozygous for the W1282X mutation revealed only the 204-bp band, and those from individuals homozygous for the AF508 detected only the 99 + 105-bp doublet. The 27-bp band could not be detected as it migrated out ofthe gel (see Fig. 3 ). Densitometry analysis oftwo individuals heterozygous for the W1282X and the normal alleles are presented in Fig. 4, lanes 1 and 7. The analysis revealed a ration of 2:1 for the WI 282X to the normal allele in each lane. This experiment was repeated by analysis ofthree additional individuals heterozygous for the WI 282X and the normal allele. The densitometry analysis revealed also a 2:1 ratio between the W1282X and the normal allele in each lane (data not shown). Analysis of two individuals heterozygous for the W1282X and the AF508 mutations are presented in Fig. 4 , lanes 2 and 6. The analysis revealed in each lane a 1:3 ratio between the W1282X and AF508 alleles, respectively. Subsequently, the same blot was hybridized to the exon 21 DNA-PCR product, which is expected to hybridize to the same 204and 99-bp bands (Figs. 3  and 4 ). The pattern of bands was identical to that detected by the exon 20 DNA-PCR probe, confirming that the 105and the 99-bp bands are indeed inseparable on the gel (data not shown). In addition, the ratio between the W1282X and the AF508 or the normal alleles, in each lane, were the same as those revealed by exon 20 DNA-PCR probe. In summary, our results show that in patients heterozygous for the W1282X and the AF508 or the normal alleles, similar levels of mRNA from the two alleles are found in each individual.
Discussion
In this study we present an analysis of the CF mRNA levels in nasal epithelial cells from CF patients carrying the nonsense mutation, W 1282X. Altogether, 19 CF chromosomes carrying the WI 282X mutation were studied, from patients with various degrees ofpulmonary disease. Understanding the effect ofthe nonsense mutation W1282X on mRNA levels is significant to the understanding of the phenotype-genotype association in this group of patients. cDNA reversed transcribed from and 7) ; two CF patients heterozygous for the W1282X and AF508 mutations (lanes 2 and 6); three CF patients homozygous for the W1282X mutation (lanes 3, 4, and 8); and a CF patient homozygous for the AF508 mutation (lane 5). The sizes (bp) of the digested fragments are indicated. nasal epithelial total RNA was revealed in five CF patients homozygous for the nonsense mutation W1282X using exon 20 DNA-PCR products as probes. The hybridization results revealed the existence of RT-PCR products from CF patients homozygous for the W1282X mutation ( Fig. 1 ). Furthermore, sequencing of the cDNA-nested PCR products generated from the homozygous patients carrying the W1282X mutation showed the expected sequence with the W 1282X mutation (Fig. 2) . These results indicate that the level of mRNA in patients homozygous for the W1282X mutation is not severely reduced by the premature termination mutation, as was found for termination mutations in other genes.
Exon skipping due to missense and nonsense mutations has been shown in several genes (33) (34) (35) . The results of our study also exclude the possibility of exon skipping due to the W1282X nonsense mutation.
We initially examined the relative levels of mRNA transcripts in individuals heterozygous for the WI 282X and the AF508 or the normal alleles by allele-specific oligonucleotide hybridization. Unexpectedly, the RT-PCR products of the W1282X allele could not be detected. Even RT-PCR products that had previously been detected by exon 20 DNA-PCR product as the probe could not be detected by allele specific oligonucleotide hybridization. The reason for this discrepancy is not clear to us. It might be the result of interference by secondary structure ofthe oligonucleotide, the inability ofthe oligonucleotide to detect low levels of RT-PCR products, or both.
However, we were able to detect the expected size RT-PCR bands generated from individuals heterozygous for the W1282X mutation by MnlI digestion and subsequent hybridization to exon 20 and 21 DNA-PCR products. In heterozygotes who carry both the W1282X and the normal alleles, the levels of the RT-PCR from the W1282X alleles were slightly higher than those of the AF508 alleles (ratio of 2:1, respectively). In heterozygotes who carry the W1282X and the AF508 alleles, the levels ofthe RT-PCR from the W1282X allele were slightly lower than those from the AF508 allele (3:1, respectively). Since the number of patients in each group was small, the significance of these fluctuations could not be evaluated. It is, however, clear that the mRNA levels of the W1282X allele are not severely reduced. Furthermore, our results indicate that negative hybridization results using oligonucleotides as probes must be confirmed by other methods.
Similar Levels of W1282X and AF508 Cystic Fibrosis Allele mRNA 1505
Recently, Rolfini et al. (36) reported that in patients homozygous for another nonsense mutation in exon 20, RI 262X, the mRNA levels seems very similar to those obtained in normal and AF508 homozygous patients. In addition, Hamosh et al. (37) reported that patients heterozygous for the W1282X mutation have severe deficiency of mRNA derived from the W1282X allele. This conclusion was based on hybridization with an oligonucleotide specific for the W1282X mutation. Severe deficiency of mRNA derived from another nonsense mutation, G542X, was also reported in that study. In addition, in a previous study (27) , severe deficiency of mRNA of the R553X and W1316X mutations was reported; these conclusions were also based on hybridization to oligonucleotides. Further studies using different detection tests are needed to verify the conclusions from the negative results obtained for the G542X, W1316X, and the R553X mutations.
The results of our study on CF patients carrying the W1282X mutation together with the results of the study on patients homozygous for the R1262X mutation suggest that mutations in exon 20 of the CFTR gene have no effect on mRNA levels. Since these two mutations are located towards the 3' end ofthe gene, the results are compatible with the polar effects of nonsense mutations found in other genes (16) . However, more studies on the effects of nonsense mutations towards the 5' end of the CF gene are needed before general conclusions can be drawn. It is expected that a truncated protein would be produced from the W1282X and the R 1262X alleles.
Patients homozygous for the W1282X mutation were found to have severe presentations of the CF disease, like patients homozygous for the AF508 mutation (28) . The results of our study indicate that the severe clinical phenotype is not necessarily due to a null phenotype resulting from severe deficiency of mRNA. In addition, it is important to emphasize that the pulmonary disease of the patients in this study varied and was not correlated with age. The oldest patient in the group was 35 yr old and his pulmonary disease was rather mild (forced expiratory volume in 1 s = 45%). We have shown that this variability in the pulmonary disease is not a result of variable mRNA levels. Thus, the severity progression and variability of pulmonary disease are affected by other, as yet unknown factors.
